ArticleInternational journal of clinical and experimental pathology2019
PD-L1 expression in colon cancer and its relationship with clinical prognosis.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 67 citations in OpenAlex.
- WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.Oncotarget · 2026Article
- The prognostic significance of B7-H3 expression in patients with advanced colorectal cancer.BMC cancer · 2026Article
- Bowel obstruction in mismatch repair-deficient colorectal cancer with excellent response to immunotherapy: a case series.Annals of coloproctology · 2026Article
- Article
- Single-cell RNA sequence analysis reveals USP32 as a therapeutic target to mitigate PD-L1-driven colorectal tumorigenesisTheranostics · 2026Article
- Liver metastasis of colorectal cancer: Mechanism and clinical therapy (Review).Oncology reports · 2025Review
- Effect of Alpha1 Antitrypsin on PD-1/PD-L1 and EGFR in Colitis-Associated Colorectal Cancer BALB/c Mouse ModelAsian Pacific journal of cancer prevention : APJCP · 2025Article
- Immunohistochemical expression of PD-L1 in colorectal carcinoma among black patients and the clinicopathological correlates: a cross-sectional study.BMC gastroenterology · 2025Article
- PD-L1 importance in malignancies comprehensive insights into the role of PD-L1 in malignancies: from molecular mechanisms to therapeutic opportunities.Clinical and experimental medicine · 2025Review
- Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Evaluation of immune checkpoint inhibitors for colorectal cancer: A network meta‑analysis.Oncology letters · 2024Article
- Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy.Materials today. Bio · 2024Article
- PD-L1 Expression in Colorectal Carcinoma Correlates with the Immune Microenvironment.Journal of gastrointestinal cancer · 2024Observational
- The Expression Patterns of Immune Checkpoint Molecules in Colorectal Cancer: An Analysis Based on Microsatellite Status.Biomedicines · 2024Article
- A Comprehensive Study on the Prognostic Value and Clinicopathological Significance of Different Immune Checkpoints in Patients With Colorectal Cancer: A Systematic Review and Meta-Analysis.Current therapeutic research, clinical and experimental · 2024Review
- Immunohistochemical Expression of Programmed Death Ligand- 1 (PD-L1) in Colorectal Carcinoma; A Cross-sectional Study.Iranian journal of pathology · 2024Article
- Article
- Characteristics, treatment, and outcome of diverticulitis after immune checkpoint inhibitor treatment in patients with malignancies.Journal of cancer research and clinical oncology · 2023Article
- Emerging phagocytosis checkpoints in cancer immunotherapy.Signal transduction and targeted therapy · 2023Review
- Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPD-L1 is closely associated with tumorigenesis and development. However, expression of PD-L1 protein in colon cancer and its significance in clinical prognosis are yet to be fully clarified. This study examined the relationship between PD-L1 expression with the clinicopathological features and prognosis of colon cancer.
methodsThis study collected cases of primary colon cancer that had not undergone preoperative chemotherapy and had complete clinical data. Eighty specimens each were obtained from cancer tissues, paracancer tissues, and normal tissues. Immunohistochemical assays were performed to detect PD-L1 expression. The relationship between PD-L1 expression and clinicopathologic features was compared. This was combined with follow-up data, to analyze the relationship between positive or negative PD-L1 expression and prognosis.
resultsAmong 80 tumor specimens, 22 cases (27.5%) showed high PD-L1 expression, 24 cases (30.0%) showed moderate expression, and 34 cases (42.5%) showed weak or no PD-L1 staining. High expression of PD-L1 in paracancer and normal tissues were 9 (11.3%) and 5 (6.3%) cases, respectively. PD-L1 expression was also positively correlated with TNM stage (
conclusionPD-L1 expression is significantly elevated in colon cancer tissues, and is closely associated with lymph node metastasis, prognosis, and survival.
Indexed as
Identifiers
31933995PMC6947132W3008571199What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.